Sales of medicinal products (MPs) and medical devices (MDs) used to relieve symptoms and treat dry eye syndrome (DES) reached RUB 10.1 billion in Q1–Q3 2025 (in retail prices including VAT). Over the same period, more than 17.1 million packages were sold. According to RNC Pharma’s “Audit of Retail Sales of Medicinal Products in Russia (total sell-out)” and “Audit of Retail Sales of Medical Devices in Russia (total sell-out)” databases, total sales grew 27.7% in value and 14.3% in volume year-on-year. Similar double-digit growth rates have been recorded for three consecutive years — in 2024, sales increased 27% in value and 15.2% in packages compared with 2023.

On the Russian retail market for ophthalmic moisturizing solutions, medical devices dominate, accounting for 88% of total market value in Q1–Q3 2025, with the remainder attributed to medicinal products. The category has a complex distribution structure: pharmacies are the primary sales channel, generating 93% of total value, but these products are also sold in optical stores and online. The role of e-commerce has been expanding steadily — from less than 2% of market value in 2022 to over 5% in Q1–Q3 2025.

In the current year, 47 brands from 30 manufacturing companies were represented on the Russian market. The undisputed leader in terms of sales value is Optinol (Jadran), which accounts for 17.6% of the retail market and shows +56% growth in rubles. The second position belongs to Systane (Alcon), with a 12.5% share and +17% growth. Gilan (Groteks) ranks third, trailing Systane by just 0.1 percentage points, but demonstrating a much stronger +27% increase, suggesting the two brands may swap places by year-end. Notably, Groteks markets three different brands in this therapeutic category, with a combined market share exceeding 15.2%.

The highest growth rates among the top 10 brands were shown by Balarpan (MNTK “Eye Microsurgery”, +58%) and Visomitin (Mitotech, +57%) — both are Russian-made medicinal products. Outside the top 10, Okostil (Pharmstandard) stands out: its sales grew 43-fold year-on-year, though the product only entered the retail market in August 2024. The weakest performance in the top 10 came from Hilo-Comod (Solco Basel), whose sales declined by 7% in value and whose volume fell by 260 thousand packages year-on-year — the steepest drop in the category.

Top-10 Brands of Ophthalmic Products for Relieving and Treating Dry Eye Syndrome by retail sales value in Russia, including pharmacies, optical stores, and online/FMCG channels, Q1–Q3 2025